Ipsen SA
PAR:IPN

Watchlist Manager
Ipsen SA Logo
Ipsen SA
PAR:IPN
Watchlist
Price: 120 EUR 0.5% Market Closed
Market Cap: 10.1B EUR

Relative Value

The Relative Value of one IPN stock under the Base Case scenario is 145.72 EUR. Compared to the current market price of 120 EUR, Ipsen SA is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IPN Relative Value
Base Case
145.72 EUR
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
55
vs Industry
44
Median 3Y
2.7
Median 5Y
2.7
Industry
2.7
Forward
2.6
vs History
14
vs Industry
18
Median 3Y
15.5
Median 5Y
13.3
Industry
21.5
Forward
10.5
vs History
4
vs Industry
38
Median 3Y
9.5
Median 5Y
9.2
Industry
16.7
vs History
92
vs Industry
10
Median 3Y
19.7
Median 5Y
18.3
Industry
23
vs History
69
vs Industry
35
Median 3Y
2.4
Median 5Y
2.6
Industry
2.3
vs History
68
vs Industry
43
Median 3Y
2.6
Median 5Y
2.6
Industry
2.9
Forward
2.4
vs History
69
vs Industry
60
Median 3Y
3.2
Median 5Y
3.1
Industry
5.6
vs History
92
vs Industry
44
Median 3Y
7.1
Median 5Y
6.9
Industry
13.2
Forward
6.4
vs History
52
vs Industry
35
Median 3Y
12.5
Median 5Y
9.6
Industry
16.6
Forward
7.9
vs History
7
vs Industry
39
Median 3Y
9.4
Median 5Y
8.8
Industry
15.8
vs History
23
vs Industry
7
Median 3Y
15.3
Median 5Y
13.3
Industry
19
vs History
30
vs Industry
38
Median 3Y
1.8
Median 5Y
2
Industry
2

Multiples Across Competitors

IPN Competitors Multiples
Ipsen SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Ipsen SA
PAR:IPN
9.9B EUR 2.6 22.2 5.6 9.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.6B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.4 158.7
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
265.6B USD 4.1 14 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142.7B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
FR
Ipsen SA
PAR:IPN
Average P/E: 24.1
22.2
42%
0.5
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
37%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Ipsen SA
PAR:IPN
Average EV/EBITDA: 400.1
5.6
2%
2.8
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Ipsen SA
PAR:IPN
Average EV/EBIT: 1 712.6
9.5
19%
0.5
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4